Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study

Peto, Tunde, Pearce, Ian, Talks, James, de Salvo, Gabriella, Patel, Praveen J., de Silva, Samantha R., Gale, Richard P., Sivaprasad, Sobha, Varma, Deepali, Reynolds, Rhianon, Bailey, Clare, Downey, Louise, Kiire, Christine, Chi, Gloria C., Dodds, Melanie, James, Natalee, Downey, Amanda K. and Dayal, Parul 2025. Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study. Eye 10.1038/s41433-025-04059-8

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB)

Abstract

Background The Faricimab Real-World Evidence (FARWIDE) studies are evaluating real-world outcomes of eyes with diabetic macular oedema (DMO)/neovascular age-related macular degeneration (nAMD) treated with faricimab in the UK. We present results from FARWIDE-DMO for eyes with 12 months of follow-up after faricimab initiation. Methods FARWIDE-DMO includes patients with diagnosis of DMO who received ≥1 intravitreal faricimab injection after May 2022 in the diagnosed eye(s) at 1 of 35 UK National Health Service sites. All eyes had ≥12 months of follow-up after faricimab initiation as of July 2024. Treatment-naïve (TN) eyes had no prior anti-VEGF therapy or steroid implant. Previously treated (PT) eyes switched to faricimab. Baseline characteristics, visual acuity (VA) outcomes and treatment patterns were evaluated. Intraocular inflammation (IOI) and presumed infectious endophthalmitis (PIE) incidences were pooled for all nAMD/DMO eyes with any follow-up duration. Analyses are descriptive. Results 2147 eyes (1564 patients) were included (TN, 32.1%; PT, 67.9%). For TN eyes, mean (standard deviation [SD]) VA at baseline and 12 months were 63.9 (15.2) and 68.4 (16.3) Early Treatment Diabetic Retinopathy Study letters, respectively. VA remained stable in PT eyes. TN eyes received a mean (SD) of 4.5 (1.0) faricimab injections in months 1–6 and 1.9 (1.2) injections in months 7–12. PT eyes received 4.5 (1.2) injections in months 1–6 and 2.4 (1.3) in months 7–12. IOI and PIE rates were consistent with faricimab phase 3 trials. Conclusions These 1-year data support real-world effectiveness, durability and safety of faricimab in DMO.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Schools > Optometry and Vision Sciences
Publisher:	Springer Nature [academic journals on nature.com]
ISSN:	0950-222X
Date of First Compliant Deposit:	27 October 2025
Date of Acceptance:	24 September 2025
Last Modified:	29 Oct 2025 09:41
URI:	https://orca.cardiff.ac.uk/id/eprint/181903

Actions (repository staff only)

Edit Item